Privately held Prolevi Bio aims improve treatment for many patients suffering from hypoterosis. The company has developed a method that is to improve the drug release in the body and thus relieve symptoms. Preparations are underway for a phase I study that is expected to start in 2023. To take the next step in the development, Prolevi Bio is carrying out a financing round of approximately 3 million euros. CEO Sahil Gupta visited BioStock’s studio to tell us more.
Watch the interview with Prolevi Bio’s CEO Sahil Gupta below.The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.